Published online before print December 29, 2003, doi: 10.1161/01.ATV.0000114235.51044.92
© 2004 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Adenoviral Transfer of Endothelial Nitric Oxide Synthase Attenuates Lesion Formation in a Novel Murine Model of Postangioplasty Restenosis
From the Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research (J.H.v.d.T., M.L.F., T.J.C.v.B., E.A.L.B.), Gorlaeus Laboratories, Department of Cardiology, Leiden University Medical Centre (J.H.v.d.T.), and Crucell Holland B.V. (R.P., A.J.v.Z., V.M.), 2333 CN Leiden, The Netherlands.
Correspondence to Jan H. von der Thüsen, Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands. E-mail thuesen{at}lacdr.leidenuniv.nl
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Restenosis remains a major late complication of percutaneous transluminal coronary angioplasty (PTCA), for which the development of prevention strategies has thus far been hampered by the lack of a representative and practical animal model. We have, therefore, developed a murine model of PTCA-induced restenosis.
Methods and Results— Rigid probe angioplasty of pre-existing atherosclerotic lesions in the carotid arteries of ApoE-deficient mice was found to result in an increase in lesion size (0.14±0.04x105 µm2 to 0.42±0.09x105 µm2, P=0.007) with a smooth muscle cell-rich, fibrotic lesion morphology. In an additional experiment, lesions were incubated immediately after angioplasty with adenovirus bearing an endothelial nitric oxide synthase (eNOS) transgene (Ad.APT.eNOS), or an "empty" control virus (Ad.APT.empty) at a titer of 1.5x109 pfu/mL. Ad.APT.eNOS treatment was seen to lead to a 73.1% reduction in plaque size (0.27±0.04x105 µm2 versus 1.02±0.39x105 µm2, P=0.07), which translated to a significantly lowered average degree of stenosis (33.6±4.1% versus 74.6±14.0%, P=0.02). Ad.APT.eNOS also decreased lesional collagen content from 29.1% to 4.8% (P<0.001).
Conclusion— We believe that we have established a representative murine model of postangioplasty restenosis, which may serve to elucidate the mechanisms underlying restenosis and to evaluate potential antirestenotic therapies.
Key Words: atherosclerosis • restenosis • mouse model • gene therapy • eNOS
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Since its introduction 25 years ago,1 the long-term outcome of percutaneous coronary revascularization procedures has been blemished by the occurrence of restenotic luminal narrowing. An extensive and diverse range of therapeutic approaches has been evaluated for their potential in the prevention of restenosis, including the technique of arterial stenting, which now constitutes a routine and efficacious procedure in most catheterization laboratories.2,3 The topical application of antirestenotic preparations at the time of angioplasty may be a practical and effective alternative to stenting, partly due to the availability of porous balloon catheters that permit the introduction of high concentrations of such compounds at the time of angioplasty. These may be administered as a naked or complexed compound, or in the shape of an (viral) expression vector in the case of polypeptides, which offers the advantage of prolonged secretion and therefore extended duration of effectivity. Promising protein mediators that could be transferred by the latter method include cell cycle regulators, such as p21, 4 growth factor decoys, as has recently been demonstrated with the transforming growth factor-ß type II receptor, 5 and enzymes, such as endothelial nitric oxide synthase (eNOS).6 The latter has been particularly closely scrutinized, and is believed to hold considerable potential in human postangioplasty restenosis, but has thus far only been evaluated in single injury, nonatherosclerotic animal models.6–8
A wide variety of such models has been developed, which usually entail a single transluminal vascular injury, such as balloon angioplasty in rabbits,9 rats,10 and pigs,11 and wire denudation of murine carotid arteries.12 The neointima formed in these models, depending on the species and the degree of hypercholesterolemia, tends to be hypercellular, highly enriched in 
smooth muscle cell actin (ASMA) content, and relatively devoid of extracellular matrix components.13–15
In clinical practice, however, atherosclerotic lesions form the lipid-rich and inflammatory "soil" of restenosis, which is reflected histologically by the presence of foam cells in the restenotic neointima.16,17 Moreover, pre-intervention plaque burden has been found to be a predictor of restenosis after angioplasty without18 and with stent implantation.19 The quest for improved reliability and clinical relevance of preclinical models for postangioplasty restenosis has led to the introduction of double injury protocols, in which dilatation is inflicted on pre-existing atherosclerotic lesions. Size limitations have thus far restricted such studies to larger experimental animals, including rabbits20 and Yucatan micropigs.21 Atherosclerosis-prone mice, however, including apolipoprotein E22 (apoE-/-) and LDL receptor (LDLr-/-) deficient mouse strains, 23 should be considered highly suitable alternatives in view of their practicality and highly representative atherosclerotic lesion morphology. We therefore aimed to develop a practical murine model of restenosis, based on transluminal dilatation of pre-existing atherosclerotic lesions.
We have previously described the site-controlled induction of carotid atherosclerosis in apoE-/- and LDLr-/- mice by placement of a perivascular collar.24 The location of these plaques permits intravascular instrumentation and adenovirus instillation,25 using the external carotid artery as a portal of entry. In the first part of the current study, we established the feasibility of rigid-probe angioplasty of plaques obtained by this technique to effect restenotic neointima formation in ApoE-/- mice. The resulting plaques were subsequently used as a substrate for the evaluation of the antirestenotic potential of adenovirus-mediated transfer of eNOS in this model.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Adenovirus Generation and Cell Transduction
To generate the replication defective recombinant serotype 5 adenovirus expressing a human eNOS construct (Ad.APT.eNOS), the eNOS cDNA was subcloned in pAdApt, which contains a cassette for transgene expression containing the CMV promoter, polylinker, and SV40 polyA (HhaI-AvrII fragment, Invitrogen). This latter fragment enables generation of recombinant adenovirus by homologous recombination with a large cloned adenovirus fragment containing nucleotides 3534 to the right end of Ad5 after cotransfection in PER.C6 packaging cells. Large batches were grown in suspension cultures on PER.C6 cells, and viruses were purified using a two step CsCl purification. An analogous method was employed to generate the replication defective empty adenovirus vector Ad.APT.empty, which was used as a control. Efficiency of virus transduction was determined with adenovirus carrying a ß-galactosidase transgene under control of a CMV promoter (Ad.CMV.lacZ).
Surgery and Gene Transfer
Bilateral pericarotid collar insertion was performed in female apoE-/- mice, aged 10 to 12 weeks, as described.24 Rigid angioplasty probes were fashioned by placement of epoxy resin beads (0.55 mm diameter, Perfecta International, Goes, The Netherlands) on a nylon wire (0.1 mm diameter, Silstar, Japan), in analogy with the method described by Zhou et al.26 Six weeks after insertion, the collars were removed and a probe was inserted into the common carotid artery through an incision in the external carotid artery. This intravascular probe was passed and retracted five times through the stenotic segment to effect damage to the collar-induced atherosclerotic plaque (Figure 1A). In the initial experiment, the animals were sacrificed after having been left on a chow (n=6) or a western-type (n=8) diet for an additional three weeks. In a second experiment, immediately after angioplasty, 10 to 20 µL of Ad.APT.empty, Ad.APT.eNOS, or Ad.CMV.lacZ suspension (1.5*109 pfu/mL) were incubated for 10 minutes in the right common carotid artery.
|
Tissue Harvesting and Histological Analysis
Three weeks after angioplasty, carotid artery specimens were obtained and transverse 5 µm cryosections prepared after in situ perfusion fixation with formalin as described.24 Cryosections were routinely stained with hematoxylin (Sigma Diagnostics) and eosin (Merck Diagnostica, Darmstadt, Germany). ß-Galactosidase was demonstrated by incubation with x-gal (1 mg/mL; Eurogentec, Seraing, Belgium) at 37°C for 4 hours. Sections were stained immunohistochemically with antibodies against a macrophage-specific antigen (MOMA-2; a kind gift of Prof. Dr. G. Kraal), ASMA (clone 1A4, Sigma), eNOS, and inducible nitric oxide synthase (iNOS) (rabbit polyclonal antibodies, both from BD Biosciences Pharmingen, Franklin Lakes, NJ).
Morphometry and Statistical Analysis
Hematoxylin-eosin stained sections of the carotid arteries were used for morphometric analysis, as described.24 In short, the intimal surface area was calculated by subtracting the patent lumen area from the area circumscribed by the internal elastic lamina, while the degree of stenosis was determined by dividing the intimal area by the total area confined by the internal elastic lamina (x100%). The collagen-positive area was determined by computer-assisted color-gated measurement of Masson’s trichrome stained sections, and divided by the total intimal surface area to arrive at the collagen/intima ratio. Vessel section examination was performed in a blinded fashion at 100 µm intervals. Values are expressed as mean±SEM. A two-tailed, nonpaired Student’s t test was employed in the comparison of individual groups. A level of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Double Injury Restenosis Model
Early Effects
In preliminary experiments, passage of the rigid angioplasty catheter was found to lead to disruption of the atherosclerotic plaque in all cases, and to a break in the internal elastic lamina in the majority of animals treated, as histologically determined immediately after the procedure. One week after angioplasty, thrombus was found to be present in 2 out of 8 angioplastied vessels, accompanied by incomplete obstruction of the lumen and evidence of recanalization (data not shown).
Late Effects
Three weeks after the procedure, angioplasty was found to have led to a significant increase in plaque size compared with the untreated contralateral artery in the animals fed a western-type diet (1.00±0.18x105 µm2 versus 0.40±0.12x 105 µm2, P=0.016, Figure 1B). The effect was particularly pronounced in the chow-fed group, however, with a 3-fold increase in plaque size (0.14±0.04x105 µm2 to 0.42±0.09x 105 µm2, P=0.007). Postangioplasty plaque size (P=0.032), intima/media ratio (P=0.033), and intima/lumen ratio (P=0.028) were significantly higher in the cholesterol-fed animals compared with the chow-fed group (Table 1). Histological and immunohistochemical analysis also revealed differences in plaque composition between these two groups, as depicted in two representative staining series in Figure 2. No differences in lipid content were found on oil-red-O staining, but the plaques of cholesterol-fed animals were seen to be less cellular and more necrotic, especially in the core of the lesion (Figure 2A and 2B). The ASMA content was substantially higher in chow-fed animals, particularly on the luminal side of the plaque (Figure 2C and 2D), while no significant differences were uncovered with respect to the macrophage-positive area (Figure 2E and 2F). Based on these findings, the lesion morphology observed in chow-fed animals was judged to be more representative of postangioplasty restenosis and to possess a greater discriminative power for the evaluation of antirestenotic therapies. Therefore, in all following studies, the western-type diet was discontinued after the angioplasty procedure.
|
|
Local Adenoviral Transduction
Transduction Efficiency
In vivo dose finding studies using Ad.APT.eNOS in noncollared arteries revealed that a titer of 1.5x109 pfu/mL, incubated intravascularly for 10 minutes, afforded endothelial overexpression without inducing cytopathic damage (as judged by the absence of endothelial denudation, endothelial cell swelling, or adhesion of leukocytes). One week after transluminal transduction, endothelial eNOS staining was found to have been raised significantly above background level by Ad.APT.eNOS incubation (Figure 3 A and 3B), and this titer was therefore adopted for all subsequent transduction experiments. Initial adenoviral transduction studies in this model were performed immediately after angioplasty with adenovirus carrying a ß-galactosidase gene instead of eNOS to facilitate the unequivocal identification of cells expressing the transgene. One week after adenovirus instillation, the transduced arteries were stained for ß-galactosidase activity. In the area denuded by the angioplasty probe in the distal common carotid artery, efficient transduction of medial smooth muscle cells was found to have occurred, with efficiencies of up to 82% (Figure 3C). In the angioplastied plaque, medial transduction was minimal, but transduction was prominent in the smooth muscle cell-rich area adjoining the lumen, with maximal transduction efficiencies averaging 24.2±18.4% (n=3) of the entire plaque cell population (Figure 3D). Comparable staining patterns were achieved 1 week after transduction with Ad.APT.eNOS, both with respect to media (Figure 3E) and plaque staining (Figure 3F). Three weeks after treatment, however, expression levels of eNOS were low and comparable to those seen in the control group. Endogenous iNOS expression was demonstrated in macrophages associated with suture material used to tie off the external carotid artery, whereas iNOS expression remained below detection level in the plaque and the media in both groups at 1 week and 3 weeks after transduction (data not shown).
|
eNOS Transduction Studies
Lesions were incubated with Ad.APT.empty (n=4) or Ad.APT.eNOS (n=5) immediately after angioplasty. Body weight, plasma cholesterol levels, and plasma triglyceride levels were unaffected by local adenovirus administration, compared with untreated controls (Table 2). Three weeks after angioplasty, the maximal plaque surface area was found to be reduced by 73.1% in the Ad.APT.eNOS treated group compared with the Ad.APT.empty treated animals (0.27±0.04x105 µm2 versus 1.02±0.39x105 µm2, P=0.07). This translated to a decrease in the intima/media ratio (4.3±1.9 to 1.1±0.3, P=0.09) and a significantly lowered average degree of stenosis (33.6±4.1% versus 74.6±14.0%, P=0.02, Figure 4A) in the Ad.APT.eNOS group. On Masson’s trichrome staining, Ad.APT.eNOS treated plaques were found to contain significantly less collagen than Ad.APT.empty treated lesions. The proportion of the neointima positive for collagen was decreased from 29.1% to 4.8% (P<0.001). A large increase in ASMA staining was found following Ad.APT.eNOS instillation, but the difference was not significant due to excessive variation (124.8±74.6 µm2 and 1262.2±828.5 µm2, respectively [P=0.34]).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We have established a model of neointima formation following angioplasty of pre-existing atherosclerotic lesions, which is, to our knowledge, the first example of true restenosis in murine arteries. Angioplasty in this model leads to plaque disruption, endothelial denudation, and medial damage. When a chow diet is administered after the procedure, the resulting neointima is typified by its complex composition: rich in smooth muscle cells and collagen, yet containing residual macrophages and extracellular lipid deposits. Both the immediate and the long-term effects observed in this model are therefore reminiscent of the histological appearances that are characteristic of human postangioplasty restenosis.16,17 The neointima found in most conventional murine models of restenosis, on the other hand, is almost exclusively based on smooth muscle cell proliferation as a result of a single arterial injury, and thus typical of in-stent restenosis.16,17 A wide range of injurious stimuli has previously been employed in this context, including vascular ligation, 27 endothelial denudation,12,28 perivascular cuff placement, 29 and photochemical injury.30
Several of these models have been used in the evaluation of protocols aimed at the prevention of neointima formation, of which the transfer of eNOS is regarded as particularly promising.31 Thus, eNOS gene transfer has been found to reduce intimal hyperplasia after balloon injury of rat carotid8,32 and porcine coronary arteries.7 Notwithstanding the overtly beneficial effect of NO in these models, direct extrapolation of these data to postangioplasty restenosis on an atherosclerotic background is not necessarily warranted. Firstly, the efficiency and tissue distribution of adenoviral transduction in most of these models differ markedly from those found after angioplasty of pre-existing plaques. For instance, we have found intact endothelium to be relatively impermeable to adenovirus suspensions, whereas endothelial denudation led to efficient transduction of medial smooth muscle cells, and angioplasty of atherosclerotic lesions enables transduction of periluminal smooth muscle cells. Secondly, in a nonoxidative milieu, gene transfer of NOS has predominantly antiatherogenic effects, including the inhibition of endothelial adhesion molecule expression and leukocyte extravasation33 and attenuation of smooth muscle cell proliferation and migration.34,35 In a setting of increased oxidative stress, however, as exemplified by the highly inflammatory conditions within an atherosclerotic plaque, NO may react with superoxide to form peroxynitrite (ONOO-).36 At low concentrations, the effects of ONOO- are similar to those ascribed to NO, but at higher concentrations it is a powerful and toxic oxidant. Moreover, ONOO- is formed from equimolar concentrations of NO and superoxide, and adequate dosing of NOS is therefore likely to be of considerable importance in an oxidative environment to avoid undesired proinflammatory effects. This likelihood is emphasized by the finding that deficiency of eNOS has been found to accelerate de novo atherosclerosis in apoE-/- mice,37 whereas deficiency of the more active inducible isoform (iNOS) attenuates atherosclerosis and reduces plasma levels of lipid peroxides.38,39 A beneficial effect of eNOS transfer to atherosclerotic lesions can therefore not be considered to be a foregone conclusion, especially because eNOS itself has been found to be capable of generating superoxide if depleted of its cofactor tetrahydrobiopterin (BH4).40 To optimize conditions for the assessment of the effect of local eNOS gene transfer in our model of postangioplasty restenosis, we initially ensured that we were using a virus titer and an incubation period which did not induce cell damage, inflammation, or iNOS expression in the vessel wall. The titer thus arrived at, 1.5x109 pfu/mL, is comparatively low for local vascular transduction, and we believe this to be related to the activity of the APT promoter, which has been shown to afford expression levels an order of magnitude higher than conventional CMV promoters.
Using this titer, we have shown eNOS to exert a beneficial effect on postangioplasty restenosis, both with respect to total plaque size and collagen deposition. Expression of eNOS was demonstrated in the media and plaques of Ad.APT.eNOS-incubated vessels 1 week after the procedure, but did not extend to three weeks after adenovirus instillation. This is in agreement with the temporal expression pattern afforded by most first generation adenoviruses. Expression of eNOS, however, coincided with the peak of neointimal cell proliferation (which is thought to occur approximately one week after angioplasty), a time point which could therefore be considered to be the most effective time for expression of a transgene aimed at limiting smooth muscle cell proliferation in the neointima. Nitric oxide has previously also been shown to modulate muscle cell function from a synthetic to a contractile phenotype, which is reflected by increased expression of markers of smooth muscle cell differentiation41 and reduction of collagen synthesis.42–45 These effects may account for the attenuation of collagen deposition and the trend toward increased ASMA expression observed in our model. Collagen-sclerotic tissue is an attribute of restenosis after percutaneous transluminal coronary angioplasty (PTCA), particularly in diabetic patients.46,47 We therefore believe our postangioplasty lesion morphology to be representative of this type of partially-fibrotic neointima, which contributes toward its validation as a model for the elucidation of molecular processes involved in nonstent restenosis after balloon angioplasty. Moreover, this model may prove to be a valuable substrate for the evaluation of antirestenotic therapies that might obviate the need for stent application. The accessibility of these lesions to intravascular application is very well suited to localized gene therapeutic approaches, whether these be viral or nonviral in nature.
|
Acknowledgments |
|---|
Acknowledgments
This study was supported by grant no. M93.001 from The Netherlands Heart Foundation.
Received August 19, 2003; accepted December 11, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979; 301: 61–68.[Abstract]
2. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS, Walker C, Stagg J, Buchbinder M, Teirstein PS, Topol EJ, Savage M, Perez JA, Curry RC, Whitworth H, Sousa JE, Tio F, Almagor Y, Ponder R, Penn IM, Leonard B, Levine SL, Fish RD, Palmaz JC. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991; 83: 148–161.
3. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): Executive summary. A report of the Am College of Cardiology/Am Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). Endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001; 103: 3019–3041.
4. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995; 96: 2260–2268.
5. Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of a secreted transforming growth factor-ß type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation. 2001; 104: 2595–2601.
6. Janero DR, Ewing JF. Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Rad Biol Med. 2000; 29: 1199–1221.[CrossRef][Medline] [Order article via Infotrieve]
7. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C, Zoldhelyi P, Gerard R, Collen D. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998; 97: 1274–1281.
8. Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P, Van de Werf F, Collen D, Janssens SP. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 1998; 98: 919–926.
9. Faxon DP, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis. 1982; 2: 125–133.
10. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983; 49: 327–333.[Medline] [Order article via Infotrieve]
11. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985; 57: 105–112.
12. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993; 73: 792–796.
13. Coats WD, Whittaker P, Cheung DT, Currier JW, Han B, Faxon DP. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation. 1997; 95: 1293–1300.
14. Bennett MR, O’ Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Therapeutics. 2001; 91: 149–166.[CrossRef][Medline] [Order article via Infotrieve]
15. Murakami S, Toda Y, Seki T, Munetomo E, Kondo Y, Sakurai T, Furukawa Y, Matsuyama M, Nagate T, Hosokawa N, Nagata K. Heat shock protein (HSP) 47 and collagen are upregulated during neointimal formation in the balloon-injured rat carotid artery. Atherosclerosis. 2001; 157: 361–368.[CrossRef][Medline] [Order article via Infotrieve]
16. Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R. Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates. Chest. 1995; 108: 815–820.
17. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol. 1999; 84: 462–466.[CrossRef][Medline] [Order article via Infotrieve]
18. Jain SP, Jain A, Collins TJ, Ramee SR, White CJ. Predictors of restenosis: a morphometric and quantitative evaluation by intravascular ultrasound. Am Heart J. 1994; 128: 664–673.[CrossRef][Medline] [Order article via Infotrieve]
19. Shiran A, Weissman NJ, Leiboff B, Kent KM, Pichard A, Satler LF, Wu HS, Leon MB, Mintz GS. Effect of preintervention plaque burden on subsequent intimal hyperplasia in stented coronary artery lesions. Am J Cardiol. 2000; 86: 1318–1321.[CrossRef][Medline] [Order article via Infotrieve]
20. Faxon DP, Sanborn TA, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Restenosis following transluminal angioplasty in experimental atherosclerosis. Arteriosclerosis. 1984; 4: 189–195.
21. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation. 1994; 89: 2816–2821.
22. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468–471.
23. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92: 883–893.
24. von der Thüsen JH, van Berkel ThJC, Biessen EAL. Induction of rapid atherogenesis by perivascular carotid collar placement in ApoE-/- and LDLr-/- mice. Circulation. 2001; 103: 1164–1170.
25. von der Thüsen JH, Kuiper J, Fekkes ML, de Vos P, van Berkel ThJC, Biessen EAL. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- Mice. FASEB J. 2001; 15: 2730–2732.
26. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, Yin M, Coffin JD, Kong L, Kranias EG, Luo W, Boivin GP, Duffy JJ, Pawlowski SA, Doetschman T. Fibroblast growth factor 2 control of vascular tone. Nat Med. 1998; 4: 201–207.[CrossRef][Medline] [Order article via Infotrieve]
27. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997; 17: 2238–2244.
28. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000; 20: 335–342.
29. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.[Medline] [Order article via Infotrieve]
30. Kikuchi S, Umemura K, Kondo K, Saniabadi AR, Nakashima M. Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening. Arterioscler Thromb Vasc Biol. 1998; 18: 1069–1078.
31. Channon KM, Qian H, George SE. Nitric oxide synthase in atherosclerosis and vascular injury: insights from experimental gene therapy. Arterioscler Thromb Vasc Biol. 2000; 20: 1873–1881.
32. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995; 92: 1137–1141.
33. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999; 99: 2979–2982.
34. Sato J, Nair K, Hiddinga J, Eberhardt NL, Fitzpatrick LA, Katusic ZS, O’Brien T. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res. 2000; 47: 697–706.
35. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 1999; 19: 2871–2877.
36. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 1998; 97: 108–112.
37. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001; 104: 448–454.
38. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000; 165: 3430–3435.
39. Kuhlencordt PJ, Chen JQ, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001; 103: 3099–3104.
40. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998; 95: 9220–9225.
41. West NEJ, Qian HS, Guzik TJ, Black E, Cai SJ, George SE, Channon KM. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation. 2001; 104: 1526–1532.
42. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res. 1995; 76: 305–309.
43. Rizvi MA, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol. 1997; 29: 1779–1789.[CrossRef][Medline] [Order article via Infotrieve]
44. Myers PR, Tanner MA. Vascular endothelial cell regulation of extracellular matrix collagen: role of nitric oxide. Arterioscler Thromb Vasc Biol. 1998; 18: 717–722.
45. Fang S, Sharma RV, Bhalla RC. Enhanced recovery of injury-caused downregulation of paxillin protein by eNOS gene expression in rat carotid artery. Mechanism of NO inhibition of intimal hyperplasia? Arterioscler Thromb Vasc Biol. 1999; 19: 147–152.
46. Pickering JG, Ford CM, Chow LH. Evidence for rapid accumulation and persistently disordered architecture of fibrillar collagen in human coronary restenosis lesions. Am J Cardiol. 1996; 78: 633–637.[CrossRef][Medline] [Order article via Infotrieve]
47. Moreno PR, Fallon JT, Murcia AM, Leon MN, Simosa H, Fuster V, Palacios IF. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol. 1999; 34: 1045–1049.
This article has been cited by other articles:
 |
|
 |
|
  H. Suzuki, K. Kimura, H. Shirai, K. Eguchi, S. Higuchi, A. Hinoki, K. Ishimaru, E. Brailoiu, D. N. Dhanasekaran, L. N. Stemmle, et al. Endothelial Nitric Oxide Synthase Inhibits G12/13 and Rho-Kinase Activated by the Angiotensin II Type-1 Receptor: Implication in Vascular Migration Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Weinmeister, R. Lukowski, S. Linder, C. Traidl-Hoffmann, L. Hengst, F. Hofmann, and R. Feil Cyclic Guanosine Monophosphate-dependent Protein Kinase I Promotes Adhesion of Primary Vascular Smooth Muscle Cells Mol. Biol. Cell, October 1, 2008; 19(10): 4434 - 4441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lukowski, P. Weinmeister, D. Bernhard, S. Feil, M. Gotthardt, J. Herz, S. Massberg, A. Zernecke, C. Weber, F. Hofmann, et al. Role of Smooth Muscle cGMP/cGKI Signaling in Murine Vascular Restenosis Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1244 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor Endocrinology, December 1, 2006; 147(12): 5914 - 5920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Partovian, Z. Zhuang, K. Moodie, M. Lin, N. Ouchi, W. C. Sessa, K. Walsh, and M. Simons PKC{alpha} Activates eNOS and Increases Arterial Blood Flow In Vivo Circ. Res., September 2, 2005; 97(5): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||